Page 57 - Read Online
P. 57
Balakrishnan et al. J Cancer Metastasis Treat 2022;8:27 https://dx.doi.org/10.20517/2394-4722.2022.33 Page 17 of 17
118. Michels T, Shurin GV, Naiditch H, Sevko A, Umansky V, Shurin MR. Paclitaxel promotes differentiation of myeloid-derived
suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol 2012;9:292-300. DOI PubMed PMC
119. Sevko A, Michels T, Vrohlings M, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells
and chronic inflammation in the spontaneous melanoma model. J Immunol 2013;190:2464-71. DOI PubMed PMC
120. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel:
suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010;16:4583-94. DOI PubMed PMC
121. Schilling B, Sucker A, Griewank K, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J
Cancer 2013;133:1653-63. DOI PubMed
122. Yuan H, Cai P, Li Q, et al. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-
derived suppressor cell accumulation. Biomed Pharmacother 2014;68:751-6. DOI PubMed
123. Tarhini AA, Edington H, Butterfield LH, et al. Immune monitoring of the circulation and the tumor microenvironment in patients
with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014;9:e87705. DOI PubMed PMC
